Straits Times Index
3,326.38 +12.24 (+0.37%) Nikkei
39,173.15 +368.50 (+0.95%) Hang Seng
17,999.06 -28.65 (-0.16%) FTSE 100
8,281.55 0.00 (0.00%) Bitcoin USD
61,074.28 -1,168.01 (-1.88%) CMC Crypto 200
1,268.78 +19.66 (+1.57%)
EDIT Nov 2024 7.500 call
| Previous close | 0.3300 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 7.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.3300 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksEditas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
GlobeNewswireEditas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA RUBY oral pres
- GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA EdiTHAL poster presentation on Friday, June 14 at 6 p.m. CEST/Noon EDT CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.
